Manhattan School of Music (MSM) is a renowned private music conservatory located in New York City, founded in 1917-1918 by pianist and philanthropist Janet D. Schenck. Originally established as the Neighborhood Music School in East Harlem, MSM has built a strong reputation for excellence in music education, influenced by notable artists like Pablo Casals and Harold Bauer. The school offers a range of academic programs, including Bachelor of Music, Master of Music, and Doctor of Musical Arts degrees. MSM specializes in classical and jazz performance, composition, conducting, and music education, and features a prominent opera program. Its campus in Morningside Heights includes instructional spaces, performance venues, and a residence hall, with facilities like the Hubbard Recital Hall, which houses a distinguished Aeolian-Skinner organ. MSM attracts a diverse student body of aspiring professional musicians from around the world, providing rigorous training and numerous performance opportunities. The institution is dedicated to fostering professional musicianship in both classical and jazz traditions.
Started with nothing more than a vision and an entrepreneurial spirit, AmeriLux International was formed in May 2004. AmeriLux is a value-adding distributor of multiwall and corrugated polycarbonate sheet products, PVC sheet and liner panels, and steel coil. Headquartered in De Pere, Wisconsin, AmeriLux sources and distributes materials from and to companies around the world. It is by building and maintaining strategic, win-win partnerships with vendors, customers, and employees that AmeriLux is able to profitably – and sustainably – grow its business. With an emphasis on customer service and support, AmeriLux International seeks to provide its customers with creative, cost-effective solutions to their unique challenges. This solutions-focused mentality has driven facility expansions and key equipment investments, enabling AmeriLux to provide a variety of fabrication services, component assembly, and turn-key manufacturing solutions. Strongly committed to educating the architectural, building, and construction communities on the benefits of using its products, AmeriLux International provides distance learning courses, webinars, and in-person presentations whereby continuing education units can be earned. These online educational programs are free, one-hour-long programs that focus on topics such as energy efficiency, polycarbonate glazing solutions, and sustainable design. This has led to a greater grass roots demand for their products. To reduce lead times and improve on-time delivery with key customers, AmeriLux International started AmeriLux Transportation — a trucking company with its own drivers and equipment — in June 2012. AmeriLux Transportation is a direct delivery carrier and regularly operates in the US. With the recent formation of AmeriLux Logistics, AmeriLux now has access to a network of qualified carriers and a wide range of freight shipping services - yet another offering to better serve the marketplace!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.